Balancing safety and efficacy in pediatric asthma management.
In the treatment of childhood asthma, balancing safety and efficacy is key to achieving optimal therapeutic benefit. Inhaled corticosteroids (ICS), because of their efficacy, remain a cornerstone in managing persistent pediatric asthma, but also are associated with significant adverse effects, including growth suppression. Consequently, careful attention must be given to balancing their safety and efficacy, which should include an understanding of airway patency and systemic absorption (dose, disease severity, propellant and lipophilicity of inhalant), bioavailability (inhalation technique, propellant, delivery devices, and hepatic first-pass metabolism), techniques for using minimum effective doses (dosing time, add-on therapy), and reduction of other exacerbating conditions (allergens, influenza, upper-respiratory diseases). The growth-suppressive effects of ICS may be most evident in children with: 1) mild asthma because the relatively high airway patency may facilitate increased levels of deposition and steroid absorption in more distal airways, and 2) evening dosing that may reduce nocturnal growth hormone activity. A step-down approach targeting a minimum effective dose and once-daily morning dosing is suggested for achieving the most acceptable safety/efficacy balance with ICS. The achievement of regular, safe, and correct ICS use requires significant knowledge and time for both caregiver and patient. Chromones, methylxanthines, long-acting beta-agonists, and leukotriene receptor antagonists are currently available alternatives to ICS for the control of persistent childhood asthma. Chromones are safe but, like methylxanthines, are difficult to use and frequently result in compromised effectiveness. Long-acting beta-agonists are not recommended as monotherapy for persistent asthma. Several factors that support leukotriene receptor antagonists as a therapeutic option for mild-to-moderate persistent pediatric asthma include established efficacy, good safety profiles, and simple, oral dosing. Physicians must evaluate and compare the balance of safety and efficacy for each agent to determine the appropriate asthma therapy for individual patients.
Skoner
David P
DP
Section of Allergy and Immunology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA. skonerd@chplink.chp.edu
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000318:Adrenergic beta-Agonists / Q000009:adverse effects / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism; D001682:Biological Availability; D002675:Child, Preschool; D002867:Chromones / Q000009:adverse effects / Q000627:therapeutic use; D006130:Growth Disorders / Q000139:chemically induced; D006801:Humans; D007223:Infant; D020024:Leukotriene Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D009330:Nebulizers and Vaporizers; D010349:Patient Compliance; D013806:Theophylline / Q000009:adverse effects / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D002867:Chromones; D020024:Leukotriene Antagonists; D013806:Theophylline